Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00555906 · ClinicalTrials.gov registry record · Phase 2
An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
A Phase 2 study of Multiple Myeloma, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 19
- Study locations
NCT00555906 is a Phase 2 study of Multiple Myeloma that has completed, run by Pfizer. The registered enrollment target is 53 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The trial reports 19 study locations across 10 states.
The verdict
NCT00555906, a Phase 2 study of Multiple Myeloma, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 19
- Study locations
Study Summary
This is a Phase 1/2 study evaluating the safety and anti-tumor activity of PD 0332991 in combination with Velcade® \[bortezomib\] and dexamethasone in patients who have received at least one previous treatment for multiple myeloma.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Bortezomib
- DRUG PD 0332991
Study Locations (19)
Missouri
- Washington University School of Medicine - St Louis
- Barnes-Jewish Hospital - St Louis
- Washington University School of Medicine - St Louis
Other
- Vseobecna fakultni nemocnice v Praze - Prague
- Universitaetsklinikum Heidelberg - Heidelberg
- Klinikum Johannes-Gutenberg -Universitaet, III. Medizinische Klinik und Poliklinik - Mainz
Illinois
- Northwestern Medical Faculty Foundation - Chicago
- Northwestern Memorial Hospital/Main Labs - Chicago
Kansas
- University of Kansas Medical Center - Kansas City
- University of Kansas Cancer Center and Medical Pavilion - Westwood
New York
- Roswell Park Cancer Institute - Buffalo
- New York Presbyterian, Weill Cornell Medical College - New York
Pennsylvania
- University of Pennsylvania Abramson Cancer Center - Philadelphia
- University of Pittsburgh Cancer Institute - Pittsburgh
South Carolina
- Hollings Cancer Center - Charleston
- Medical University of South Carolina - Charleston
Maryland
- University of Maryland - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2008-01 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00555906
The ClinicalTrials.gov registry entry for NCT00555906 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.
NCT00555906 reports 19 study locations spanning 10 distinct geographic areas - top geographies include Missouri, Other, Illinois.
Frequently Asked Questions
What is clinical trial NCT00555906 about?
NCT00555906 is a clinical study titled "An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.". This is a Phase 1/2 study evaluating the safety and anti-tumor activity of PD 0332991 in combination with Velcade® \[bortezomib\] and dexamethasone in patients who have received at least one previous treatment for multiple myeloma.
What is the current status of trial NCT00555906?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2008-01. Estimated completion is 2013-03.
What conditions does trial NCT00555906 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00555906?
The interventions under investigation include: Dexamethasone (DRUG), Bortezomib (DRUG), PD 0332991 (DRUG).
Who is sponsoring clinical trial NCT00555906?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00555906 being conducted?
This trial has 19 study locations across Illinois, Kansas, Maryland, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.